EGFP-encoding Oncolytic Herpes Simplex Virus 1 (ΔΔICP0), CMV-EGFP(Cat#: RepOV-0020XY)

This product is a EGFP encoding oncolytic herpes simplex virus, which is based on HSV-1 with ICP0 deleted. The deletion of ICP0 were attenuated for viral growth, and impaired for viral reactivation when equivalent latent infections were established in vivo. This product can be used in oncolytic virotherapy research and further recombinant HSV construction.

Specifications

Family Herpesviridae
Species Herpes simplex virus
Serotype Herpes simplex virus 1
Backbone HSV-1 (ΔΔICP0)
Backbone Background Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. Modified Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic ability.
Gene Modification ΔΔICP0
Promoter CMV
Transgene EGFP
Type of Transgene Reporter gene
Related Target/Protein Enhanced green fluorescent protein
Capsid Modification None
Titer >1*10^8 PFU
Related Diseases Osteosarcoma

Transgene

Alternative Names EGFP, egfp, enhanced green fluorescent protein
Gene ID 20473140

Information

Introduction EGFP, derived from Aequorea victoria, is a unique GFP variant which contains chromophore mutations that make the protein 35 times brighter than wild-type GFP, and is codon-optimized for higher expression in mammalian cells. These changes in the GFP coding sequence provide an enhanced GFP (EGFP) that greatly increases the sensitivity of the reporter protein.

Customer Reviews and Q&As

There are currently no customer reviews or questions for EGFP-encoding Oncolytic Herpes Simplex Virus 1 (ΔΔICP0), CMV-EGFP (RepOV-0020XY). Click the button below to contact us or submit your feedback about this product.

All products and services are for Research Use Only. Not For Clinical Use.

Other products

PRODUCTS

Online Inquiry